SPARC and cancer: Furthermore, in vivo and in vitro application of myokines, such as irisin [16–19], decorin [20–24], interleukin-6 (IL-6) [25, 26], interleukin-15 (IL-15) [27, 28], secreted protein acidic and rich in cysteine (SPARC) [29–32], and oncostatin M (OSM) [33–35], have reduced the growth and migration of various types of cancer cell lines, including prostate [19, 20, 24–27, 30].